BLOG/πŸ‡ΊπŸ‡ΈUnited StatesΒ·Β·daily

HHS & Healthcare Contracts Intelligence β€” March 12, 2026

HHS & Healthcare Contracts Intelligence

2 total filings analysed

Executive Summary

HHS obligated $796M across two health R&D contracts, led by a dominant $724M BARDA biotech award to nonprofit Advanced Technology International, providing 7+ year spending visibility but no equity upside. Bullish signal from Technical Resources International's $73M (potential $337M) NIAID clinical research contract, with 50% of obligated funds already outlayed since 2024. Low average outlays (~10% of obligated value) highlight execution risks, while long-term horizons to 2030-2031 underscore sustained health preparedness trends warranting sector monitoring.

Tracking the trend? Catch up on the prior HHS & Healthcare Contracts Intelligence digest from March 07, 2026.

Investment Signals(3)

  • Small Biz Wins Large NIAID R&D Contract(HIGH)
    β–²

    Technical Resources International secured $72.7M obligated (up to $337M options) cost-plus-fixed-fee deal via full/open competition, with $36.1M outlayed.

  • BARDA Locks in $724M Long-Term Biotech R&D(MEDIUM)
    β–²

    Full obligation including options through 2030-12-31 signals multi-year funding stability in health preparedness.

  • Nonprofit Recipient Caps Investor Upside(HIGH)
    β–²

    Largest award to nonprofit limits direct equity benefits despite massive scale.

Risk Flags(3)

  • Execution[MEDIUM RISK]
    β–Ό

    Low outlays ($24M/724M for ATI; options unexercised for TRI) signal potential delays in $796M drawdown.

  • Execution[HIGH RISK]
    β–Ό

    Firm fixed price on $724M BARDA award exposes to cost overruns over 7+ years.

  • Market[MEDIUM RISK]
    β–Ό

    Nonprofit status blocks equity upside from 91% of total obligated value.

Opportunities(2)

  • β—†

    $337M ceiling via options on TRI NIAID contract, building on $36M outlays.

  • β—†

    Full/open competition awards in BARDA/NIAID R&D signal rising small biz access to long-term funds.

Sector Themes(2)

  • β—†

    Contracts span 7+ years to 2030-2031 with $796M obligated, focusing on biotech/clinical services amid health preparedness priorities.

  • β—†

    91% value to nonprofit vs 9% to for-profit small biz highlights access barriers but open comp opportunities.

Watch List(3)

  • πŸ‘

    {"entity"=>"Technical Resources International, Inc.", "reason"=>"$337M potential if options exercised; 50% obligated outlayed signals momentum.", "trigger"=>"Option exercises or outlays >$50M"}

  • πŸ‘

    {"entity"=>"Advanced Technology International", "reason"=>"$724M obligation with minimal $24M outlay flags drawdown risks/opportunities.", "trigger"=>"Outlays exceeding 10% ($72M) or extensions"}

  • πŸ‘

    {"entity"=>"BARDA/NIAID R&D Pipelines", "reason"=>"Patterns in full/open comp awards to nonprofits/small biz indicate sector funding trends.", "trigger"=>"New awards >$100M or accelerated disbursements"}

Get daily alerts with 3 investment signals, 3 risk alerts, 2 opportunities and full AI analysis of all 2 filings

πŸ‡ΊπŸ‡Έ More from United States

View all β†’
HHS & Healthcare Contracts Intelligence β€” March 12, 2026 | Gunpowder Blog